The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene ...

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

The Centers for Medicare and Medicaid Services has named 33 states, as well as Washington, D.C., and Puerto Rico, as participants in its Cell and Gene Therapy Access Model, which is designed to treat ...

The model was initially launched by the Biden administration in February 2023, and CMS announced that SCD would be the first focus of the model the following January. This is the ...

The US regulator has launched a new national initiative to help Medicaid programs fund gene therapies for sickle cell disease ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

A total of 33 states, plus the District of Columbia and Puerto Rico, agreed to participate in the U.S. CMS’ voluntary, outcomes-based program aimed at helping state Medicaid programs cover high-priced ...

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

Despite questions around stagnation, experts argue that cell and gene therapies are evolving rapidly –driven by innovation in manufacturing, decentralisation, and targeted delivery.

Regenerative medicine is gaining serious momentum in 2025 as scientific advances, regulatory progress, and payer acceptance converge to push the sect ...

What happens if the US ties drug prices to other nations? Discover how the most-favored-nation policy could shake the global ...

The idea is how do we really make affordable cell and gene therapy products. While research is going on in a few labs and institutes, lots has to be done to take it to the market.” ...